Ark Therapeutics, FIN-70120 Kuopio, Finland.
Hum Gene Ther. 2010 Apr;21(4):381-96. doi: 10.1089/hum.2010.017.
In 1971 Judah Folkman proposed the concept of antiangiogenesis as a therapeutic target for cancer. More than 30 years later, concept became reality with the approval of the antivascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab as a first-line treatment for metastatic colorectal cancer. Monoclonal antibodies and small molecular drugs are the most widely applied methods for inhibition of angiogenesis. The efficacy of these antiangiogenic modalities has been proven, in both preclinical and clinical settings. Although angiogenesis plays a major role in wound healing, hypoxia, and in the female reproductive cycle, inhibition of angiogenesis seems to be a relatively safe therapeutic option against cancers, and has therefore become a logical arena for a wide range of experimentation. The twentieth century has shown the boom of gene therapy and thus it has been applied also in the antiangiogenic setting. This review summarizes methods to induce antiangiogenic responses with gene therapy and discusses the obstacles and future prospects of antiangiogenic cancer gene therapy.
1971 年， Judah Folkman 提出了抗血管生成作为癌症治疗靶点的概念。30 多年后，随着抗血管内皮生长因子（VEGF）单克隆抗体贝伐单抗被批准用于转移性结直肠癌的一线治疗，这一概念成为现实。单克隆抗体和小分子药物是抑制血管生成最广泛应用的方法。这些抗血管生成方式的疗效已在临床前和临床环境中得到证实。尽管血管生成在创伤愈合、缺氧和女性生殖周期中起主要作用，但抑制血管生成似乎是一种针对癌症相对安全的治疗选择，因此已成为广泛实验的合理领域。20 世纪见证了基因治疗的繁荣，因此它也被应用于抗血管生成领域。本文综述了用基因治疗诱导抗血管生成反应的方法，并讨论了抗血管生成癌症基因治疗的障碍和未来前景。
